News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Balance sheet
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article provides an overview of Annexon (ANNX.US) stock ratings from four analysts in the last quarter, with a consensus price target ranging from $8 to $27. The analysts show a generally bullish sentiment, reflected in their diverse ratings and price targets, indicating varying …
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Koninklijke Philips (ENXTAM:PHIA) has drawn renewed attention after updating its long-term agreement with Exor. The move allows Exor to raise its shareholding to 22%, while existing governance …
Citizens JMP upgraded Annexon (NASDAQ:ANNX) from "underperform" to "market perform," while the overall analyst consensus remains a "Hold" with an average price target of $15.33. The company recently reported a quarterly loss of $0.28 per share, missing consensus estimates. Investors are looking ahead to …
Annexon (NASDAQ:ANNX) reported a second-quarter loss of $0.28 per share, which was wider than the analyst consensus of $0.24 per share, leading to a 6.37% fall in pre-market trading. The biopharmaceutical company attributed the increased loss to higher spending on its late-stage clinical programs, …
Annexon, Inc. has announced an expansion to its Phase 3 ARCHER II trial for vonaprument, a treatment for dry age-related macular degeneration with geographic atrophy. The expansion includes adding a Month 24 dual primary endpoint to complement the existing Month 15 primary endpoint, alongside …
Annexon, Inc. (ANNX) reported a Q2 2026 basic and diluted loss per share of $0.28, an improvement from $0.34 in the prior year. The clinical-stage biopharmaceutical company posted a net loss of $55.3 million as it continues to invest in its pipeline for inflammatory-related …
Annexon (NASDAQ:ANNX) reported second-quarter earnings, missing analysts' consensus estimates by $0.05 with a loss of $0.28 per share. Despite the earnings miss, the company highlighted positive clinical trial data for tanruprubart in Guillain-Barré syndrome and expanded its ARCHER II geographic atrophy trial. Annexon also …
Annexon (ANNX) announced an expansion of its ARCHER II trial for vonaprument in geographic atrophy, adding a 24-month primary endpoint to capture longer-term efficacy data, alongside the existing 15-month endpoint. The company also provided updates on its Guillain-Barré syndrome (GBS) program, with tanruprubart advancing …
Annexon reported a wider-than-expected Q2 2026 loss of $0.28 per share, leading to a 6.37% premarket stock decline. Despite the earnings miss, the clinical-stage biotech highlighted positive clinical progress for its Guillain-Barré syndrome program, tanruprubart, and expanded the ARCHER II geographic atrophy trial to …
Annexon (Nasdaq: ANNX) reported its second-quarter 2026 financial results, including a net loss of $55.3 million, but also announced a new $200 million credit facility to extend its cash runway into 2028. The company is advancing its neuroinflammatory pipeline, expanding the Phase 3 ARCHER …
Annexon reported rapid, clinically meaningful improvements in strength among all 10 patients in the first US and European cohort of its open-label FORWARD study for Guillain-Barré syndrome (GBS) following a single tanruprubart infusion. These results, including ambulation for bedbound patients and ventilator liberation, are …
Royal Philips Clinician and patient with Azurion and IntraSightClinician and patient with Azurion and IntraSight Exor logoExor logo Disney themes incorporated into Philips Ambient Experience for MRIDisney themes incorporated into Philips Ambient Experience for MRI Nurses at central monitoring stationNurses at central monitoring station …
This article announces that Annexon Inc. filed a Form 8K on August 10th. The filing is brief and does not contain additional details beyond the date of the filing and the company involved.
Annexon, Inc. (NASDAQ:ANNX) has appointed retinal surgeon Mark S. Blumenkranz, M.D., M.M.S., to its board of directors. Concurrently, Muneer Satter will step down from the board after more than 11 years of service. Blumenkranz brings extensive experience from Stanford University and has co-founded several …
Annexon has appointed retinal surgeon and biotech entrepreneur Mark S. Blumenkranz to its board of directors. Blumenkranz, a Stanford ophthalmology professor emeritus and co-director of its Ophthalmic Innovation Program, has a strong background in founding and leading ophthalmic companies. This appointment follows the stepping …
Annexon, Inc. (Nasdaq: ANNX) has appointed Dr. Mark S. Blumenkranz, a distinguished retinal surgeon and biotechnology entrepreneur, to its board of directors. Dr. Blumenkranz brings over four decades of experience in retinal disease innovation, which will be crucial as Annexon advances its late-stage clinical …
Renaissance Technologies LLC reduced its stake in Annexon, Inc. (NASDAQ:ANNX) by 32.2%, selling 258,300 shares but still retaining 544,300 shares valued at approximately $3.0 million. While Renaissance Technologies reduced its holdings, other institutional investors like AQR Capital Management and Acadian Asset Management increased their …
Annexon, Inc. announced early positive results from the first ten U.S. and European patients in its open-label FORWARD study for Guillain-Barré syndrome (GBS) treated with tanruprubart. The study demonstrated rapid, clinically meaningful improvements in strength and reduced disability within days of a single infusion, …
This article provides an update on Annexon Inc (ANNX) stock news, earnings, analyst ratings, and key developments. It notes that more news is expected soon and invites users to stay tuned. The article also presents current stock performance data for ANNX.
Wells Fargo has reaffirmed its Buy rating on Annexon (ANNX.US), holding its target price at $27. This continued endorsement suggests the firm's confidence in Annexon's future performance.
State Street Corporation has disclosed a 6% holding in Annexon Inc. (ANNX), amounting to 9,824,321 common shares, as per a Schedule 13G filing. The shares are held for passive investment purposes with shared voting power over 9,572,419 shares and shared dispositive power over all …
Goldman Sachs has reiterated a Neutral rating and $7.00 price target on Annexon Biosciences (NASDAQ: ANNX) following the release of initial data from its FORWARD study for Guillain-Barré syndrome (GBS). The study showed rapid and meaningful improvement in patients, supporting a planned biologics license …
Annexon reported positive early results from its FORWARD study for Guillain-Barré syndrome, demonstrating rapid functional and strength gains in all ten treated patients within approximately one week. The company noted that patients, including severe cases, showed quicker recovery than expected, and the safety profile …
Annexon, Inc. reported positive clinical outcomes from the initial U.S. and European patient cohort of its GBS FORWARD Study. The study is evaluating tanruprubart, and the findings were disclosed in a current report filed with the SEC on August 6, 2026. This announcement highlights …
This article from Investing.com reports on an 8K filing by Annexon Inc. for August 6th, 2026. The content provides basic details of the filing along with an image credited to Reuters. The article itself is very brief and mostly surrounded by financial market data, …
Annexon (NASDAQ:ANNX) is projected to release its Q2 2026 earnings before market open on Thursday, August 13th, with analysts expecting a loss of $0.23 per share and revenue of $6.50 million. The company's stock recently traded near $5.37, and analyst sentiment is mixed, resulting …
Strategic innovation and commitment to operational excellence bolster extended relationship NORTH BETHESDA, Md., August 05, 2026--(BUSINESS WIRE)--Sodexo, a leading provider of high-quality food and facilities management solutions, has renewed its partnership with Deaconess Health System. Valued at approximately $23 million annually, the renewed agreement …
Search by ticker symbol or company name and select a result to open its chart.